Lenders Accelerate Synergy CHC's $18.9M Term Loan After Default
SNYR sits 15% above its 52-week low of $0.082 on elevated volume (6.4× avg).
Summary
Synergy CHC's lenders have accelerated its term loan, declaring the full $18.9 million balance immediately due and payable after the previously disclosed default.
Key Events · Legal and Risk Events · SNYR
-
Loan Accelerated
ACP Agency, at the direction of required lenders, terminated all commitments and declared all obligations under the Credit Agreement immediately due and payable.
-
Amount Due
Approximately $18.9 million was immediately due and payable as of August 21, 2026, up from the $17.6 million disclosed in the August 11 default notice, exclusive of additional interest, fees, costs and expenses.
-
Existential Liquidity Crisis
The accelerated amount is more than 12 times the company's entire market capitalization, making repayment from operations or equity infeasible.
-
Cascade of Distress
This follows the August 11 default notice, the July 29 disclosure that Costco will discontinue FOCUSfactor products, and the August 21 Nasdaq delisting notice for failing to file its Q2 10-Q.
Analysis · SNYR · Life Sciences
The default disclosed on August 11 has now escalated to full acceleration. Lenders have terminated all commitments and declared the entire $18.9 million balance immediately due and payable. For a company with a market cap under $1.5 million and a stock price near $0.09, this is an existential liquidity event. The company cannot repay this amount from operations, and the acceleration removes any remaining runway. This follows a cascade of distress: Costco discontinuing FOCUSfactor products, a Nasdaq delisting notice for failing to file its Q2 10-Q, and now a formal demand for repayment.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 43.3% of the 1014 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNYR was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $0.08 to $3.18. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.